Vyome Holdings, Inc. (HIND)
2.22
-0.01
(-0.45%)
USD |
NASDAQ |
Sep 04, 16:00
2.16
-0.06
(-2.70%)
After-Hours: 20:00
Vyome Holdings Research and Development Expense (Quarterly) : 0.5067M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.5067M |
| March 31, 2026 | 0.6664M |
| December 31, 2025 | 0.3783M |
| September 30, 2025 | 0.0397M |
| June 30, 2025 | 0.0801M |
| March 31, 2025 | 0.0903M |
| December 31, 2024 | 0.0675M |
| September 30, 2024 | 0.0668M |
| June 30, 2024 | 0.399M |
| March 31, 2024 | 0.484M |
| December 31, 2023 | 0.739M |
| September 30, 2023 | 0.542M |
| June 30, 2023 | 0.581M |
| March 31, 2023 | 0.453M |
| December 31, 2022 | 0.441M |
| September 30, 2022 | 0.583M |
| June 30, 2022 | 0.747M |
| March 31, 2022 | 0.745M |
| December 31, 2021 | 0.277M |
| September 30, 2021 | 1.571M |
| Date | Value |
|---|---|
| June 30, 2021 | 0.103M |
| March 31, 2021 | 0.571M |
| December 31, 2020 | 0.879M |
| September 30, 2020 | 0.859M |
| June 30, 2020 | 0.465M |
| March 31, 2020 | 1.257M |
| December 31, 2019 | 1.492M |
| September 30, 2019 | 1.174M |
| June 30, 2019 | 1.418M |
| March 31, 2019 | 2.439M |
| December 31, 2018 | 2.338M |
| September 30, 2018 | 2.368M |
| June 30, 2018 | 3.352M |
| March 31, 2018 | 2.639M |
| December 31, 2017 | 2.689M |
| September 30, 2017 | 2.798M |
| June 30, 2017 | 2.76M |
| March 31, 2017 | 2.40M |
| December 31, 2016 | 2.605M |
| September 30, 2016 | 2.169M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cardiac Biotech Solutions, Inc. | 0.0132M |
| Anika Therapeutics, Inc. | 7.341M |
| Enovis Corp. | 31.69M |
| Edwards Lifesciences Corp. | 278.90M |
| Perspective Therapeutics, Inc. | 20.40M |